Search results for "Tolerance induction"

showing 10 items of 38 documents

Human limbal fibroblast-like stem cells induce immune-tolerance in autoreactive T lymphocytes from female patients with Hashimoto’s thyroiditis

2017

Background Due to their “natural immune privilege” and immunoregulatory properties human fibroblast-like limbal stem cells (f-LSCs) have acquired great interest as a potential tool for achieving immunotolerance. Hashimoto’s thyroiditis (HT) is the most common thyroid autoimmune disease and cause of hypothyroidism. To date, conventional hormone replacement therapy and unspecific immunosuppressive regimens cannot provide a definitive cure for HT subjects. We explored the immunosuppressant potential of human f-LSCs on circulating lymphomonocytes (PBMCs) collected from healthy donors and female HT patients. Methods We assessed the immunophenotyping of f-LSCs, both untreated and after 48 h of pr…

0301 basic medicineAdultMedicine (miscellaneous)Hashimoto DiseaseCD8-Positive T-LymphocytesInflammatory diseasesMajor histocompatibility complexBiochemistry Genetics and Molecular Biology (miscellaneous)Settore MED/13 - EndocrinologiaProinflammatory cytokineImmune tolerancelcsh:Biochemistry03 medical and health scienceschemistry.chemical_compoundHuman limbal stem cells Hashimoto’s thyroiditis Immunoregulation Tolerance induction Inflammatory diseasesImmune privilegeImmune ToleranceMedicineHumanslcsh:QD415-436Tolerance inductionCells CulturedAgedlcsh:R5-920biologybusiness.industryResearchStem CellsInterleukinImmunoregulationCarboxyfluorescein succinimidyl esterCell BiologyHashimoto’s thyroiditisFibroblastsMiddle AgedTh1 Cells030104 developmental biologychemistryImmunologybiology.proteinHuman limbal stem cellsMolecular MedicineCytokinesFemaleStem cellbusinesslcsh:Medicine (General)CD8Stem Cell Research & Therapy
researchProduct

IL-10-Modulated Human Dendritic Cells for Clinical Use: Identification of a Stable and Migratory Subset with Improved Tolerogenic Activity.

2015

Abstract Dendritic cells (DCs) are key regulators of protective immune responses and tolerance to (self-)Ags. Therefore, the scientific rationale for the use of tolerogenic DC therapy in the fields of allergies, autoimmunity, and transplantation medicine is strong. In this study, we analyzed the tolerogenic capacity of IL-10–modulated DC (IL-10DC) subpopulations to identify a DC subset that combines potent immunosuppressive activities with valuable immune properties for clinical implementation. IL-10DCs consist of two phenotypically distinct subpopulations: CD83highCCR7+ IL-10DCs and CD83lowCCR7− IL-10DCs. Suppressor assays with activated effector T cells revealed that CD4+ regulatory T cel…

0301 basic medicineChemokineReceptors CCR7medicine.medical_treatmentImmunologyImmunoglobulinsBiologymedicine.disease_causeLymphocyte ActivationT-Lymphocytes RegulatoryAutoimmunity03 medical and health sciencesImmune systemAntigens CDCell MovementmedicineImmune ToleranceImmunology and AllergyHumansIL-2 receptorCells CulturedInflammationMembrane GlycoproteinsChemokine CCL21Interleukin-2 Receptor alpha SubunitCell DifferentiationDendritic CellsInterleukin-10Interleukin 10Tolerance induction030104 developmental biologyCytokineImmunologybiology.proteinImmunotherapyCCL21Journal of immunology (Baltimore, Md. : 1950)
researchProduct

TGF-β inhibitor Smad7 regulates dendritic cell-induced autoimmunity

2017

TGF-β is an anti-inflammatory cytokine whose signaling is negatively controlled by Smad7. Previously, we established a role for Smad7 in the generation of autoreactive T cells; however, the function of Smad7 in dendritic cells (DCs) remains elusive. Here, we demonstrate that DC-specific Smad7 deficiency resulted in elevated expression of the transcription factors Batf3 and IRF8, leading to increased frequencies of CD8(+)CD103(+) DCs in the spleen. Furthermore, Smad7-deficient DCs expressed higher levels of indoleamine 2,3-dioxygenase (IDO), an enzyme associated with tolerance induction. Mice devoid of Smad7 specifically in DCs are resistant to the development of experimental autoimmune ence…

0301 basic medicineEncephalomyelitis Autoimmune Experimentalmedicine.medical_treatmentCellular differentiationAutoimmunitychemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyT-Lymphocytes RegulatorySmad7 ProteinImmune toleranceMice03 medical and health sciences0302 clinical medicineTransforming Growth Factor betaImmune TolerancemedicineAnimalsIndoleamine-Pyrrole 23-DioxygenaseMultidisciplinaryintegumentary systemExperimental autoimmune encephalomyelitisCell Differentiationhemic and immune systemsDendritic CellsDendritic cellTransforming growth factor betamedicine.diseaseCell biologyMice Inbred C57BLTolerance inductionBasic-Leucine Zipper Transcription Factors030104 developmental biologyCytokinePNAS PlusInterferon Regulatory FactorsImmunologybiology.proteinCytokinesSpleenCD8Signal Transduction030215 immunology
researchProduct

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

2019

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton's jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of i…

0301 basic medicineSettore BIO/17 - IstologiaB7 AntigensT cellIn Vitro TechniquesBiologyLymphocyte ActivationRegenerative medicineCell therapyUmbilical CordImmune toleranceImmunomodulation03 medical and health sciences0302 clinical medicineWharton's jellymedicineHumansWharton JellyCD276Cells CulturedCell ProliferationStem cellMesenchymal stem cellCell DifferentiationMesenchymal Stem CellsHuman umbilical cordCell biologyTransplantationTolerance induction030104 developmental biologymedicine.anatomical_structureB7-H3030220 oncology & carcinogenesisLymphocyte inhibitionRegenerative medicineCytokinesWharton’s jelly mesenchymal stromal cellsStem cell
researchProduct

Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation

2017

Defects in regulatory T cells (Treg cells) aggravate multiple sclerosis (MS) after its onset and the absence of Treg cell functions can also exacerbate the course of disease in an animal model of MS. However, autoimmune neuroinflammation in many MS models can be acutely provoked in healthy animals leading to an activation of encephalitogenic T cells despite the normal induction of immune tolerance in the thymus including thymically-produced (t)Treg cells. In contrast, neuroinflammation can be ameliorated or even completely prevented by the antigen-specific Treg cells formed extrathymically in the peripheral immune system (pTreg cells) during tolerogenic responses to relevant neuronal antige…

0301 basic medicinelcsh:Immunologic diseases. AllergyMini ReviewImmunologychemical and pharmacologic phenomenaBiologyImmune toleranceneuroinflammation03 medical and health sciences0302 clinical medicineAntigenmedicineImmunology and AllergyIL-2 receptordendritic cellsNeuroinflammationtoleranceexperimental autoimmune encephalomyelitis/multiple sclerosisMultiple sclerosisPeripheral toleranceHOPXmedicine.diseaseCD5Tolerance induction030104 developmental biologypTreg cellsImmunologyCD5lcsh:RC581-607Treg cells030215 immunologyFrontiers in Immunology
researchProduct

Editorial: Current concepts of cellular and biological drugs to modulate regulatory T cell activity in the clinic

2016

The Editorial on the Research Topic Current Concepts of Cellular and Biological Drugs to Modulate Regulatory T Cell Activity in the Clinic Regulatory T (Treg) cells are essential for the maintenance of peripheral tolerance and prevent the development of autoimmunity and allergy. While on the one hand being indispensable for the perpetuation of tolerance to harmless antigens or self-antigens, Treg cells contribute to cancer pathogenesis and progression (1). Hence, the potential to treat a multitude of different human diseases by pharmacological modulation of Treg cells is enormous. Consequently, this T cell population is in the focus of biomedical research and development. Currently, isolate…

0301 basic medicinelcsh:Immunologic diseases. AllergyRegulatory T cellT cellImmunologyPopulationAutoimmunitymedicine.disease_causeregulatory T cellsAutoimmunityAutoimmune Diseases03 medical and health sciencesmedicineImmunology and Allergyclinical studieseducationeducation.field_of_studybusiness.industryPeripheral toleranceImmunoregulationT helper cellDendritic CellsTolerance inductionEditorial030104 developmental biologymedicine.anatomical_structureHumanized mouseImmunologybusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

B?cells are not required for T?cell priming in low zone tolerance to contact allergens and contact hypersensitivity

2004

Low zone tolerance (LZT) to contact allergens is induced by epicutaneous exposure to haptens in subsensitizing doses resulting in an inhibition of contact hypersensitivity (CHS), which, in contrast, occurs after sensitization with immunogenic doses of allergens. Performing the protocol of tolerance induction resulted in robust LZT to allergens in B cell-deficient mice in vivo, indicating that B cells are not required for the induction and effector phase of LZT. However, CHS reactions in vivo were restricted in B cell-deficient mice as compared to wild-type (WT) mice. In contrast, analysis of hapten-specific T cell activation in vitro revealed a strong proliferative response of T cells deriv…

Adoptive cell transfermedicine.medical_treatmentT cellImmunologyPriming (immunology)Picryl ChlorideCD8-Positive T-LymphocytesBiologyDermatitis ContactLymphocyte ActivationInterferon-gammaMiceAdjuvants ImmunologicImmune TolerancemedicineAnimalsImmunology and AllergySensitizationB cellCell ProliferationMice KnockoutB-Lymphocytesintegumentary systemInterleukinsOxazoloneAllergensAdoptive TransferMice Inbred C57BLTolerance inductionCytokinemedicine.anatomical_structureImmunologyLymph NodesCD8European Journal of Immunology
researchProduct

DR(high+)CD45RA(-)-Tregs potentially affect the suppressive activity of the total Treg pool in renal transplant patients.

2011

Recent studies show that regulatory T cells (Tregs) play an essential role in tolerance induction after organ transplantation. In order to examine whether there are differences in the composition of the total CD4(+)CD127(low+/-)FoxP3(+)- Treg cell pool between stable transplant patients and patients with biopsy proven rejection (BPR), we compared the percentages and the functional activity of the different Treg cell subsets (DR(high+)CD45RA(-)-Tregs, DR(low+)CD45RA(-)-Tregs, DR(-)CD45RA(-)-Tregs, DR(-)CD45RA(+)-Tregs). All parameters were determined during the three different periods of time after transplantation (0-30 days, 31-1,000 days, >1,000 days). Among 156 transplant patients, 37 pat…

AdultGraft Rejectionmedicine.medical_specialtymedicine.drug_classClinical Research DesignImmune Cellslcsh:Medicinechemical and pharmacologic phenomenaMonoclonal antibodyT-Lymphocytes RegulatoryOrgan transplantationInterleukin-7 Receptor alpha SubunitYoung AdultT-Lymphocyte SubsetsBiopsymedicineHumanslcsh:ScienceKidney transplantationAgedKidneyMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RInterleukin-2 Receptor alpha Subunithemic and immune systemsForkhead Transcription FactorsHLA-DR AntigensMiddle AgedImmunologic Subspecialtiesmedicine.diseaseKidney TransplantationTransplant rejectionTransplantationTolerance inductionmedicine.anatomical_structureNephrologyImmunologyLeukocyte Common AntigensMedicinelcsh:QClinical ImmunologySurgerybusinessResearch ArticlePloS one
researchProduct

Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: D…

2019

Background: The appearance of inhibitors is the most serious complication in haemophilia A (HA) patients. The primary objective is their eradication. Up to date, immune tolerance induction (ITI) was the only therapeutic option to achieve this. Aim: To assess the efficacy of moroctocog-alpha as an ITI regimen in a population of HA patients with high-titre inhibitors. Methods: The REF.IT Registry is a retrospective-prospective study that collected data on all patients with HA and high-titre inhibitors treated with moroctocog-alpha as an ITI regimen at twelve Italian Haemophilia Centres. Results: We enrolled 27 patients, 85.2% were children. All patients were high responders, 88.9% had severe …

AdultMalemedicine.medical_specialtyPopulationHaemophilia AAlpha (ethology)030204 cardiovascular system & hematologyHaemophiliaHemophilia Ahaemophilia A with inhibitors; immune tolerance induction; moroctocog-alpha; poor-prognosis ITI patients; Adult; Child; Child Preschool; Factor VIII; Female; Hemophilia A; Humans; Immune Tolerance; Italy; Male; Prospective Studies; Retrospective Studies; Risk Factors; RegistriesImmune tolerance03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineImmune ToleranceMedicineHumansProspective StudiesRegistrieseducationHigh titrePreschoolChildGenetics (clinical)Retrospective Studiesimmune tolerance inductioneducation.field_of_studyFactor VIIIbusiness.industryHematologyGeneral Medicinehaemophilia A with inhibitormedicine.diseasepoor-prognosis ITI patientsRegimenItalymoroctocog-alphaChild PreschoolFemalebusinessComplicationhaemophilia A with inhibitors030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct

The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis

2009

Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) inhibits T-cell activation and interleukin-2 (IL-2) production. The PTPN22(gain-of-function)+1858T(+) genotypes predispose to multiple autoimmune diseases, including early-onset (non-thymomatous) myasthenia gravis (MG). The disease association and the requirement of IL-2/IL-2 receptor signaling for intrathymic, negative T-cell selection have suggested that these genotypes may weaken T-cell receptor (TCR) signaling and impair the deletion of autoreactive T cells. Evidence for this hypothesis is missing. Thymoma-associated MG, which depends on intratumorous generation and export of mature autoreactive CD4(+) T cells, is a model of au…

AdultMalemedicine.medical_specialtyThymomaAdolescentGenotypeThymomaImmunologyBiologymedicine.disease_causePolymorphism Single NucleotideWhite PeopleAutoimmunityPTPN22Young AdultAntigens CDInternal medicineMyasthenia GravisCentral tolerance inductionGeneticsmedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseaseReceptorGenetics (clinical)AgedAged 80 and overT-cell receptorProtein Tyrosine Phosphatase Non-Receptor Type 22Thymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyInterleukin-2FemaleCentral toleranceGenes & Immunity
researchProduct